Global Small Molecule Innovator Cdmo Market Growth Rate 2024, Forecast To 2033
8 Mar, 2024
The small molecule innovator CDMO market has experienced robust growth, expanding from $51.84 billion in 2023 to $56.13 billion in 2024, with a CAGR of 8.3%. This growth is driven by factors such as the rising demand for outsourcing and the increasing complexity of small molecule drugs. The market is expected to continue growing, reaching $76.46 billion in 2028, with a CAGR of 8.0%. Factors such as personalized medicine and the expansion of the biopharmaceutical pipeline will fuel this growth. Major trends include increased collaboration in the pharma industry and the utilization of single-use technologies.
Global Small Molecule Innovator CDMO Market Key Driver
The small-molecule innovator CDMO market is poised for growth due to the rising prevalence of chronic diseases. Chronic diseases, which require ongoing medical care and management, are becoming increasingly common, particularly among aging populations. Notably, projections from the National Center for Biotechnology Information highlight the significant rise in the number of individuals affected by chronic illnesses. This escalating prevalence of chronic diseases is driving demand for small-molecule innovator CDMO services, as pharmaceutical and biotech companies seek efficient solutions for developing and manufacturing treatments, leading to growth in the market.
Get A Free Sample Of The Global Small Molecule Innovator CDMO Market ReportGlobal Small Molecule Innovator CDMO Market Segments
The small molecule innovator cdmo market covered in this report is segmented –
1) Product:Small Molecule Active Pharmaceutical Ingredient(API), Small Molecule Drug Product
2) Stage:Preclinical, Clinical, Commercial
3) Therapeutic:Cardiovascular Disease, Oncology, Respiratory Disorders, Neurology, Metabolic Disorders, Infectious Disease, Other Therapeutics
4) Customer:Pharmaceutical, Biotechnology
By Geography: The countries covered in the small molecule innovator cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Asia-Pacific was the largest region in the small molecule innovator CDMO market in 2023. The regions covered in the small molecule innovator cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Small Molecule Innovator CDMO Industry Players
Thermo Fisher Scientific Inc.; Boehringer Ingelheim International GmbH; Evonik Industries AG; Lonza Group Ltd. ; Labcorp Drug Development; Catalent Inc.; Wuxi AppTec Co. Ltd.; Asymchem; Siegfried holdings; Recipharm AB; Almac Sciences Ltd.; Curia Global Inc.; Cambrex Corporation; Piramal Pharma Ltd.; Hovione; Corden Pharma GmbH; Alcami Corporation; Lifecore Biomedical Inc.; NovaTech LLC; Mikart LLC; Kymanox Corporation; August Bioservices LLC; Lyophilization Technology Inc.; LGM Pharma LLC; INCOG BioPharma Services
Get The Full Global Small Molecule Innovator CDMO Market Report
Small Molecule Innovator CDMO Market Overview
Small molecule innovator CDMO refers to a pharmaceutical division offering small-molecule drug development and manufacturing contract services. It is used in clinical trials to obtain early relative bioavailability information.